Beranda › Kelebihan Berat Badan › Arizona › Tucson
Uji klinis Kelebihan Berat Badan di Tucson, AZ
15 studi untuk Kelebihan Berat Badan mencari peserta di lokasi sekitar Tucson (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Menerima pesertaFase 3
- Synexus Clinical Research US, Inc./Orange Grove Family Practice, Tucson
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Menerima pesertaFase 3
- University of Arizona, Tucson
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Menerima pesertaFase 3
- Tucson Clinical Research Institute, Tucson
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Menerima pesertaFase 3
- Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Menerima pesertaFase 3
- Research Site, Tucson
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Menerima pesertaFase 3
- Tucson Orthopaedic Institute - North Wyatt Drive, Tucson
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Menerima pesertaFase 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Menerima pesertaFase 3
- AURORA-1 Clinical Site, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Menerima pesertaFase 3
- AURORA-2 Clinical Site, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Menerima pesertaFase 3
- Arizona Clinical Trials, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Menerima pesertaFase 3
- Arizona Clinical Trials, Tucson
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Menerima pesertaFase 3Sukarelawan sehat diterima
- ACCOMPLISH-2 Research Site, Tucson
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Menerima pesertaFase 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Menerima pesertaFase 2
- Pima Heart, Tucson
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Menerima pesertaFase 3
- ACCOMPLISH-1 Research Site, Tucson
Uji klinis Kelebihan Berat Badan di kota lain
- San Antonio, TX34 studi
- Houston, TX33 studi
- Chicago, IL28 studi
- Orlando, FL27 studi
- Las Vegas, NV23 studi
- Miami, FL23 studi
- Atlanta, GA20 studi
- Dallas, TX20 studi
- New York City, NY19 studi
- Jacksonville, FL19 studi
- Washington, DC19 studi
- Austin, TX18 studi
Studi lain di Tucson
- Kanker Payudara20 studi
- Kanker Paru Non-Sel Kecil17 studi
- Obesitas17 studi
- Kanker Metastatik14 studi
- Kanker (semua jenis)12 studi
- Penyakit Kardiovaskular12 studi
- Kanker Kolorektal11 studi
- Kanker Prostat11 studi
- Penyakit Hati Steatotik10 studi
- Gagal Jantung10 studi
- Tekanan Darah Tinggi10 studi
- Diabetes Tipe 210 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.